Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents
Katherine S Klamer, Ashish Bhargava, Leonard Johnson, Mamta Sharma, Louis D Saravolatz · 2026
Read Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents by Katherine S Klamer, Ashish Bhargava, Leonard Johnson, Mamta Sharma, Louis D Saravolatz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13213078.txt.
Description
Katherine S. Klamer and co-authors test in 2026 how well eleven drugs kill a hard-to-treat yeast in the lab. The yeast came from Michigan hospitals. It spreads in wards and kills many of the sick people it infects, so labs need to know which drugs still work.
They grew 84 yeast samples from Michigan and 27 from stock collections, then found the lowest drug dose that stopped each one. A new drug, manogepix, worked at the lowest dose of all. A drug class called echinocandins came next, and nearly all samples stayed weak against it. One sample had a gene change that made it resist that class. The old drug fluconazole worked poorly, as past reports found.
Catalog record
| CREATOR | Katherine S Klamer, Ashish Bhargava, Leonard Johnson, Mamta Sharma, Louis D Saravolatz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |